Skip to content
Markets News
Stocks1 min read

Lockheed Raises 2026 Outlook as Backlog Hits Record $230 Billion

Makkler Newsroom
October 6, 2026

Higher quarterly sales and a record order backlog supported Lockheed’s raised outlook, while fixed-price contract costs remain a concern.

Key takeaways

  • Lockheed reported second-quarter sales of $20.1 billion, up 11% year over year.
  • The company ended the quarter with a record $230 billion backlog.
  • Lockheed raised its full-year sales and earnings guidance.

Lockheed Martin raised its full-year sales and earnings outlook after reporting second-quarter sales of $20.1 billion, up 11% from a year earlier. The defense contractor ended the quarter with a record $230 billion backlog.

Net earnings per share were $7.94, compared with $1.46 a year earlier. The prior-year result included a $1.6 billion charge tied to difficulties in the Aeronautics unit and helicopter programs, which did not recur this year.

The backlog rose 38.3% year over year, supported by $65 billion in quarterly orders, including a $35 billion multiyear contract for THAAD interceptors. Lockheed now expects full-year sales of $79.75 billion to $81.75 billion and earnings per share of $29.95 to $30.65.

The improved outlook follows a difficult stretch for the shares. As of October 1, they had returned 4.51% year to date, versus 11.99% for the S&P 500, according to the article. First-quarter earnings missed estimates amid production slowdowns and higher costs on fixed-price contracts.

The article said Lockheed trades at a forward price-to-earnings ratio of 16.16, below the sector median of 18.97 and RTX’s 24.57. It attributed investor concern to the risk of further contract charges and said the company’s third-quarter results, expected later in October, would be closely watched.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.